PVLA NASDAQ
Palvella Therapeutics, Inc.
1W: -2.6%
1M: -11.3%
3M: +35.3%
YTD: +15.6%
1Y: +399.0%
$113.99
-1.93 (-1.66%)
Weekly Expected Move ±9.3%
$93
$104
$114
$125
$135
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$0.8M
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.3B
52W Range20.2-151.18
Volume143,872
Avg Volume295,906
Beta-0.12
Dividend—
Analyst Ratings
Company Info
CEOWesley H. Kaupinen
Employees14
SectorHealthcare
IndustryBiotechnology
IPO Date2015-01-02
Websitepalvellatx.com
125 Strafford Avenue
Wayne, PA 19087
US
Wayne, PA 19087
US
484 253 1461
About Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.
Latest News
Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Disease Therapy for Multiple Serious, Rare Vascular Malformations
Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology
Palvella Therapeutics approved for transfer to Nasdaq Global Market
Palvella targets 2H 2026 NDA filing while outlining >$1B peak U.S. sales potential for QTORIN rapamycin in microcystic lymphatic malformations
Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Goin Kathleen | S-Sale | 3,363 | $110.35 | 2026-05-20 |
| Goin Kathleen | S-Sale | 891 | $111.30 | 2026-05-20 |
| Goin Kathleen | S-Sale | 48 | $111.89 | 2026-05-20 |
| Goin Kathleen | S-Sale | 1,502 | $125.96 | 2026-04-15 |
| Goin Kathleen | S-Sale | 1,500 | $127.13 | 2026-04-15 |